MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/meg.0b013e3283345524

Медицинская библиотека · European journal of gastroenterology & hepatology · 2010

Terlipressin therapy for renal failure in cirrhosis.

Triantos Christos K, Samonakis Dimitrios, Thalheimer Ulrich, Cholongitas Evangelos, Senzolo Marco, Marelli Laura, Leandro Gioacchino, Patch David, Burroughs Andrew K

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVES

Renal failure is common in cirrhosis frequently due to hepatorenal syndrome (HRS). Terlipressin and albumin improve renal function with a trend to prolong survival in HRS, but prognostic factors with therapy have been poorly studied.

METHODS

Forty-five cirrhotics seen consecutively in a single centre with renal failure defined as oliguria/anuria and/or rising creatinine and no response to volume loading, without intrinsic renal disease, sepsis, gastrointestinal bleeding [median Child-Pugh score 12(8-14)/Model for End-Stage Liver Disease 29(10-40)], had intravenous terlipressin and albumin and were audited retrospectively classified into three groups: group 1 HRS type 1 (15), group 2 HRS type 2 (11) and group 3(19): not fulfilling HRS 1 or 2 criteria. Baseline median creatinine was 1.7 (0.9-5.46) mg/dl and 30 (67%) had creatinine greater than 1.5 mg/dl. All 45 patients had initial colloid/albumin and 31 continued terlipressin (2-4 mg/day) for a median 8 (2-76) days.

RESULTS

Improvement in serum creatinine occurred in 23 (51%) [(1.3 mg/dl (0.6-3.9)] compared with baseline [1.7 mg/dl (0.92-3.75)] (P<0.001). In the multivariate analysis a greater reduction in creatinine between baseline and day 4 (95% confidence interval, odds ratio: 0.25) was associated with improved survival at 6 weeks.

CONCLUSION

Albumin and terlipressin improve renal failure in the absence of sepsis in cirrhosis independently of whether HRS criteria are fulfilled or not. Improvement at 4 days of therapy is associated with better survival. Randomized studies are needed for oliguria and rising creatinine in cirrhotics even if HRS criteria are not fulfilled.

Для цитирования: Triantos Christos K, Samonakis Dimitrios, Thalheimer Ulrich, Cholongitas Evangelos, Senzolo Marco, Marelli Laura, Leandro Gioacchino, Patch David, Burroughs Andrew K. Terlipressin therapy for renal failure in cirrhosis.. European journal of gastroenterology & hepatology. 2010. DOI: 10.1097/meg.0b013e3283345524.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.